Emergent Biosolutions Inc. (EBS) SEC Filing 8-K Material Event for the period ending Thursday, October 25, 2018

Emergent Biosolutions Inc.

CIK: 1367644 Ticker: EBS

View differences made from one to another to evaluate Emergent Biosolutions Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Emergent Biosolutions Inc..


Assess how Emergent Biosolutions Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Emergent Biosolutions Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools
Ticker: EBS
CIK: 1367644
Form Type: 8-K Corporate News
Accession Number: 0001367644-18-000039
Submitted to the SEC: Thu Oct 25 2018 9:15:48 AM EST
Accepted by the SEC: Thu Oct 25 2018
Period: Thursday, October 25, 2018
Industry: Pharmaceutical Preparations
  1. Other Events

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: